Form 4: AnaptysBio Director Granted Stock Options, RSUs

AnaptysBio, Inc. Director Dennis M. Fenton was granted 5,500 stock options and 4,000 restricted stock units on January 6, 2026.

Summary

• Dennis M. Fenton, a Director of AnaptysBio, Inc., received equity awards on January 6, 2026.
• The grants include 5,500 stock options with an exercise price of $43.91 per share.
• These stock options will vest at a rate of 1/12 of the total shares monthly, commencing February 6, 2026, contingent on continued service.
• Additionally, 4,000 Restricted Stock Units (RSUs) were granted.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
• The RSUs will vest 100% on the date of AnaptysBio's 2027 annual meeting of shareholders, also subject to continued service.

Sentiment

Score: 6

Explanation: The filing reports routine equity grants to a director, which is a standard compensation practice. It aligns the director's interests with shareholders and incentivizes continued service, which is mildly positive, but does not indicate significant operational or financial news.

Positives

• Equity grants align the interests of Director Dennis M. Fenton with those of shareholders.
• The grants serve as an incentive for the director's continued service and performance.

Negatives

• Potential future dilution from the exercise of stock options and settlement of RSUs.

Future Outlook

The grants include future vesting schedules: 5,500 stock options will vest monthly starting February 6, 2026, and 4,000 RSUs will vest 100% on the date of the Issuer's 2027 annual meeting of shareholders, both contingent on the director's continued service.

Industry Context

Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, aiming to align leadership interests with long-term company performance and shareholder value. This filing reflects a routine compensation event for a director.

Comparison to Industry Standards

• Equity compensation, including stock options and restricted stock units, is a common practice for directors in publicly traded biotechnology companies like AnaptysBio, Inc.
• The vesting schedules, with monthly vesting for options and a single vesting event for RSUs tied to an annual meeting, are typical structures designed to incentivize long-term commitment and performance.
• Specific comparable companies or projects are not detailed in the filing, but such compensation structures are broadly consistent with those observed at peer companies in the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options and settlement of RSUs, but also increased alignment of director's interests with shareholder value.

Next Steps

• Monthly vesting of 5,500 stock options commencing February 6, 2026.
• Vesting of 4,000 Restricted Stock Units on the date of the Issuer's 2027 annual meeting of shareholders.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director and does not contain information that would significantly alter the investment thesis for AnaptysBio, Inc. While the grants align director interests with shareholders, they are not a primary driver for a 'buy' or 'sell' recommendation. Investors should continue to 'hold' and monitor broader company performance and strategic developments.

Keywords

AnaptysBio, ANAB, SEC Form 4, stock options, restricted stock units, equity grant, director compensation, insider transaction